Lenvatinib Mesylate Capsules Receive Drug Registration Certificate
August 13, 2026
Source: drugdu
26
On August 7th, Lu Kang Pharmaceutical(600789) announced that it has obtained a Drug Registration Certificate for Lenvatinib Mesylate Capsules from the National Medical Products Administration. This approval supports the enrichment of the company's pharmaceutical product pipeline.
Lenvatinib mesylate is a tyrosine kinase receptor inhibitor indicated for patients with unresectable hepatocellular carcinoma who have not previously received systemic therapy. Its domestic sales in 2025 and the first quarter of 2026 were RMB 649 million and RMB 419 million, respectively. The company's R&D investment in this drug was approximately RMB 8.59 million (unaudited).
In the first quarter of 2026, Lu Kang Pharmaceutical achieved revenue of 1.616 billion yuan and net profit attributable to the parent company of 53.25 million yuan.
https://finance.eastmoney.com/a/202608073835349687.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- A well-known generic drug company recalls 10 types of eye drops. August 13, 2026
- Big news! Zhejiang pharmaceutical company targets 500 million yuan lipid-lowering blockbuster drug August 13, 2026
- Subsidiary’s Tranexamic Acid Sodium Chloride Injection Receives Drug Registration Certificate August 13, 2026
- Subsidiary’s self-developed Class 1 innovative drug, bemosubalimab injection, in combination therapy, has been approved for marketing. August 13, 2026
- Hanyu Pharmaceutical has licensed 3SBio’s Smegglutide injection to commercialize the product, with sales milestones reaching up to 145 million yuan. August 13, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
